Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.
electroCore, Inc. (ECOR) is a leader in non-invasive vagus nerve stimulation therapies, providing innovative solutions for neurological conditions and wellness applications. This page serves as the definitive source for ECOR news, offering investors and professionals timely updates on regulatory developments, clinical research, and strategic initiatives.
Access curated press releases covering FDA clearances, partnership announcements, and financial results. Stay informed about advancements in gammaCore™ therapies for migraine treatment and TAC-STIM cognitive enhancement technologies. Our repository includes updates on international expansions, clinical trial outcomes, and product pipeline developments.
Bookmark this page for direct access to primary source materials from electroCore, including neuromodulation research breakthroughs and commercialization progress across healthcare and defense sectors. Regular updates ensure you maintain current awareness of ECOR's position in the evolving bioelectronic medicine landscape.
electroCore, Inc. (Nasdaq: ECOR) announced an agreement with RSK Medical Inc. to distribute its gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) in Canada. This partnership aims to provide treatment for patients with primary headache disorders, particularly migraines and cluster headaches. The agreement, with a three-year initial term, includes minimum purchase commitments. Both companies emphasize their commitment to improving patient access to innovative therapies.
electroCore, Inc. (Nasdaq: ECOR) announced that Health Improvement Scotland has published a Scottish Health Technology Group adaptation for NHS Scotland regarding the use of gammaCore for cluster headache treatment. This recommendation supports NICE guidelines from 2019, stating gammaCore can reduce attack frequency and intensity, improving patients' quality of life and saving £450 per patient in the first year. The adaptation allows for a three-month trial of gammaCore in NHS Scotland. The company aims to expand access to its treatment for cluster headache patients.
electroCore, Inc. (Nasdaq: ECOR) announced that the Centers for Medicare and Medicaid Services (CMS) published a new HCPCS code K1020 for its gammaCore Sapphire™ D device, effective April 1, 2021. This non-invasive vagus nerve stimulator code aims to enhance patient access to gammaCore therapy, which treats primary headache conditions. The decision reflects CMS’s recognition of the clinical and economic benefits of the gammaCore treatment, positioning the company for broader coverage opportunities.
electroCore (Nasdaq: ECOR) announced expected full-year 2020 revenue between $3.3M and $3.5M, reflecting over 40% growth from 2019's $2.4M. Q4 2020 net cash usage was $3.7M, better than the $4M guidance, and cash reserves at year-end totaled $22.6M. The company continues initiatives in COVID-19 and opioid use disorder treatments, alongside favorable data from the PREMIUM II migraine study. Expansion efforts included distribution agreements in Eastern Europe and government channels, despite challenges posed by COVID-19. Management expresses optimism for future growth opportunities.
electroCore, Inc. (Nasdaq: ECOR) has partnered with Pro Medical Baltic UAB to exclusively distribute its gammaCore Sapphire™ non-invasive vagus nerve stimulation (nVNS) therapy for headache disorders in Eastern Europe, including Lithuania, Latvia, Belarus, Kazakhstan, and Ukraine. The three-year agreement aims to enhance market access for gammaCore's treatment of cluster headaches and migraines. Pro Medical Baltic has experience in neuromodulation and a robust network of physicians, which is expected to benefit the introduction of nVNS therapy in the region.
electroCore (Nasdaq: ECOR) announced the top-line results of its PREMIUM II study, which evaluated the efficacy of gammaCore™ in reducing migraine days. Despite early termination due to COVID-19, results indicated that patients using gammaCore experienced 3.1 fewer migraine days compared to 2.3 in the sham group. Notably, 44.9% of gammaCore users achieved at least a 50% decrease in migraine days versus 26.8% for the sham group. The results also showed significant improvements in quality of life and migraine-associated disability, especially in patients with aura. Complete study results are expected in early 2021.
BASKING RIDGE, N.J., Dec. 07, 2020 – electroCore, a bioelectronic medicine company (Nasdaq: ECOR), will present at the 13th Annual LD Micro Main Event Conference on December 14, 2020. The presentation is scheduled for 2:40-3:00 PM EDT. Investors can register for the conference HERE. A webcast replay will be available on the company's website post-conference. electroCore focuses on non-invasive vagus nerve stimulation therapy for migraines and cluster headaches.
electroCore, Inc. (Nasdaq: ECOR) announced that its gammaCore non-invasive vagus nerve stimulator will be evaluated in a randomized study for treating opioid use disorders, led by Dr. Douglas Bremner at Emory University. The study will enroll 40 subjects to assess the effectiveness of nVNS in reducing opioid cravings. The initiative is part of addressing the growing health crisis of addiction in the U.S. and is supported by the National Institute on Drug Abuse. The project aims to explore innovative treatments during the critical withdrawal period.
electroCore, Inc. (Nasdaq: ECOR) reported Q3 2020 revenue of approximately $1.1 million, a 44% sequential increase and 58% year-over-year growth. The company reduced its quarterly cash burn to $4.1 million and secured an Emergency Use Authorization for gammaCore Sapphire™ CV to treat COVID-19 related symptoms. The Veterans Administration has initiated a clinical trial for non-invasive vagal nerve stimulation. Overall, operating expenses declined to $5.2 million, a significant drop from $11.2 million in Q3 2019, indicating cost management progress.
electroCore (Nasdaq: ECOR) has announced that CEO Dan Goldberger and CFO Brian Posner will participate in two upcoming investor conferences on November 19, 2020. The first event is the Sidoti Virtual Microcap Conference 2020, featuring a corporate presentation and 1x1 meetings from 10:45am to 11:45am ET. The second event is the Canaccord Genuity Virtual MedTech & Diagnostics Forum, also consisting of 1x1 meetings. The company specializes in non-invasive vagus nerve stimulation therapy, targeting conditions in neurology such as migraine and cluster headaches.
